Changes in smooth pursuit eye movements and the P300 component of the auditory evoked potential were studied in patients with primary degenerative dementia during a double-blind, placebo-controlled study of ergoloid mesylates (Hydergine). After 18 weeks of treatment, P300 latency and amplitude, recorded at three scalp electrode sites, had not changed significantly. Smooth pursuit gain was elevated for the drug group under some stimulus conditions, suggesting a normalization of pursuit eye movement functioning. However, the results of several other measures of the quality of pursuit eye movements failed to corroborate this finding. (J Geriatr Psychiatry Neurol 1990; 3:41-47).
Get full access to this article
View all access options for this article.
References
1.
Loew DM, Weil C.: Hydergine in senile mental impairment. Gerontology1982; 28:54-74.
2.
McDonald RJ: Hydergine: A review of 26 clinical studies. Pharmakopsychiatr Neuropsychopharmakol1979; 12:407-422.
3.
Yesavage JA, Tinklenberg JR, Hollister LE, et al: Vasodilators in senile dementias: A review of the literature . Archs Gen Psychiatry1979; 36:220-223.
4.
Hollister LE , Yesavage J.: Ergoloid mesylates for senile dementias: Unanswered questions. Ann Intern Med1984; 100:894-898.
5.
Arrigo A., Braun P., Kauchtschischwili GM, et al: Influence of treatment on symptomatology and correlated electroencephalographic (EEG) changes in the aged. Curr Ther Res1973 ; 15:417-426.
6.
Roubicek J., Geiger C., Abt K.: An ergot alkaloid preparation (Hydergine) in geriatric therapy. J Am Geriatr Soc1972; 20:222-229.
7.
Herzfeld U., Christian W., Oswald WD, et al: Zur wirkungsanalyse von Hydergin im langzeitversuch. Med Klin1972; 67:1118-1125.
8.
Matejcek M., Knor K., Piguet PV, et al: Electroencephalographic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation . J Am Geriatr Soc1979; 27:198-202.
9.
Saletu B., Grunberger J.: Antihypoxidotic and nootropic drugs: Proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations. Prog Neuropsychopharmacol Biol Psychiatry1980; 4:469-489.
10.
Donchin E., Ritter W., McCallum WC: Cognitive psychophysiology: The endogenous components of the ERP, in Callaway E, Teuting P, Koslow S (eds): Event-Related Potentials in Man. New York, Academic Press, 1978, pp 349-441.
11.
Duncan-Johnson CC: P300 latency: A new metric of information processing. Psychophysiology1981; 18:207-215.
12.
Goodin DS, Squires KC, Starr A.: Long latency event-related components of the auditory evoked potential in dementia. Brain1978; 101:635-648.
13.
Syndulko K., Hansch EC, Cohen SN, et al: Long-latency event-related potentials in normal aging and dementia , in Courjon J, Maugiere F, Revol M (eds): Clinical Application of Evoked Potentials in Neurology. New York, Raven Press, 1982, pp 279-285.
14.
Pfefferbaum A., Wenegart BG, Ford JM, et al: Clinical application of the P3 component of event-related potentials. II: Dementia, depression, and schizophrenia. Electroencephalogr Clin Neurophysiol1984; 59:104-124.
15.
Polich J., Ehlers CL, Otis S., et al: P300 latency reflects the degree of cognitive decline in dementing illness. Electroencephalogr Clin Neurophysiol1986; 63:138-144.
16.
Callaway E. , Halliday R., Naylor H., et al: Effects of scopolamine on human stimulus evaluation. Psychopharmacology1985; 85:133-138.
17.
Hammond EJ, Meador KJ, Aung-Din R., et al: Role of the cholinergic system in the generation of human cognitive evoked potentials. Neurology1987; 37:346-350.
18.
Meador KJ, Loring DW, Adams RJ, et al: Central cholinergic systems and the P3 evoked potential. Int J Neurosci1987; 33:199-206.
19.
Meador KJ, Loring DW, Lee GP, et al: In vivo probe of central cholinergic systems. J Gerontol1988; 43:158-162.
20.
Meador KJ, Loring DW, Davis HC, et al: Cholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol1989 ; 11:252-260.
21.
Exton-Smith AN , Murray N., Moffat B., et al: A pilot study of the effect of hydergine on the event-related evoked potential and on psychological and behavioral indices in dementia, in Rose FC (ed): Modern Approaches to the Dementias. Part II: Clinical and Therapeutic Aspects. Basel, Karger, 1985, pp 179-184.
22.
Kuskowski MA , Malone SM, Mortimer JA, et al: Smooth pursuit eye movements in dementia of the Alzheimer's type. Alzheimer Dis Assoc Disord1989; 3:157-171.
Hutton JT: Eye movements and Alzheimer's disease: Significance and relationship to visuospatial confusion, in Hutton JT, Kenny AD (eds): Senile Dementia of the Alzheimer Type. New York, Liss, 1985, pp 3-33.
25.
Fletcher WA , Sharpe JA: Smooth pursuit dysfunction in Alzheimer's disease. Neurology1988; 38:272-277.
26.
Reisberg B. , Ferris SH, de Leon MJ, et al: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatr1982; 139:1136-1139.
27.
Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12:189-198.
28.
McCarthy G., Wood CC: Scalp distributions of event-related potentials: An ambiguity associated with analysis of variance models. EEG andClin Neurophysiol1985; 62:203-208.
29.
Glaser EM, Ruchkin DS: Principles of Neurobiological Signal Analysis. New York , Academic Press, 1976.
30.
Cohen J., Cohen P.: Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences , 2nd ed. Hillsdale, NJ, Lawrence Erlbaum Associates, 1983.
